Cancer Prevention and Screening : (Record no. 4529)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 11303nam a22004933i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC5494679 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240724113322.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2018 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781118991060 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781118990872 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC5494679 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL5494679 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaPaEBR)ebr11601659 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1049914325 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC268 .C363 2019 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.994075 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Eeles, Rosalind A. |
| 245 10 - TITLE STATEMENT | |
| Title | Cancer Prevention and Screening : |
| Remainder of title | Concepts, Principles and Controversies. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Newark : |
| Name of producer, publisher, distributor, manufacturer | John Wiley & Sons, Incorporated, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2018. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2018. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (456 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Intro -- Title Page -- Copyright Page -- Contents -- List of contributors -- Foreword -- Prologue -- Chapter 1 Global perspectives surrounding cancer prevention and screening -- Principles of cancer control strategy -- Magnitude of the problem: Proportion of cancer globally attributable to preventable causes -- Primary prevention strategies globally -- Tobacco smoking -- Vaccination -- Screening -- General principles -- Existing screening options -- The harms of screening -- Targeted screening -- Early diagnosis -- Historical importance: Reasons for late presentation -- Targeted screening based on nonspecific symptoms -- Conclusion -- References -- Chapter 2 Public health perspectives surrounding cancer prevention and screening: The Ontario edition -- Context: Health care in Canada -- What is happening at the federal level? -- What is happening at the provincial level? Cancer Care Ontario -- The Ontario Cancer Plan -- Measuring cancer system performance in Ontario -- Cancer prevention in Ontario led by CCO -- Work at the policy level -- Work at the individual level -- Prevention research -- Public Health Ontario -- Canadian Cancer Society -- CCO's provincial cancer screening programmes -- CCO's approach to new evidence for cancer screening -- CPAC's role in cancer screening -- Conclusion -- References -- Chapter 3 Cancer screening: A general perspective -- On the nature of screening -- Assessing a screening test -- Assessing benefit from a screening test -- Lead-time bias -- Length bias -- Overdiagnosis -- The order of evidence of benefit -- The population screened -- The magnitude of screening benefit -- Screening in practice -- Conclusion -- References -- Chapter 4 The balance of cancer screening risks and benefits -- Cervical screening -- Breast screening -- Colorectal cancer screening -- Prostate cancer screening. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Psychological harms of screening -- Informed decision-making -- Conclusion -- References -- Chapter 5 Cancer screening issues in black and ethnic minority populations -- Conclusion -- References -- Chapter 6 Public awareness of cancer screening -- Awareness of cancer screening -- Beliefs relevant to cancer screening -- Perceptions of cancer risk -- Cancer fear -- Cancer fatalism -- Perceived benefits and harms of cancer screening -- Informed choice -- Intention and action -- Engagement -- Conclusion -- References -- Chapter 7 Public understanding of cancer prevention -- Public understanding of prevention -- What can we do to improve understanding? -- Case study: Online information -- Case study: The media -- Case study: The Cancer Awareness Roadshow, a face‐to‐face intervention -- Case study: Talk Cancer, training for health workers -- Communicating risk -- Conclusion -- References -- Chapter 8 Cervical cancer screening: An exemplar of a population screening programme, and cervical cancer prevention -- How do we screen for cervical precancer? -- Prevention of invasive cervical cancer: The impact of cytological screening -- Factors influencing the success of a screening programme -- Molecular-based cervical screening technologies -- Algorithms employing HPV DNA in primary screening -- The value of biomarkers in triage -- Consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors -- Risk assessment to guide cervical screening strategies -- Male Circumcision and Cervical Cancer -- Conclusions -- References -- Chapter 9 Prevention of and screening for anal cancer -- Primary prevention -- Vaccination -- Modification of behaviour and other exposures -- Secondary prevention -- Screening and treatment for cancer precursors -- Early detection and treatment of cancer -- Conclusion -- Acknowledgements -- References. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Chapter 10 The prevention of breast cancer -- Estimation of risk of breast cancer -- Clinical breast cancer prevention -- Preventive therapy (chemoprevention) -- Side effects of preventive therapy -- Other preventive agents -- Uptake of preventive therapy -- Lifestyle change -- Weight control -- Exercise -- Alcohol -- Lifestyle programmes for breast cancer risk reduction -- Risk-reducing surgery -- Conclusion -- References -- Chapter 11 Breast cancer: Population and targeted screening -- Evidence for the benefit of breast cancer screening -- Randomized controlled trials -- Observational studies -- Evidence for the benefit of screening women under age 50 -- Evidence for the benefit of screening women above age 70 -- Balance of benefits and harms -- Implementation of mammography screening in different countries -- Organized screening programmes -- Opportunistic screening -- Individualized screening -- New technologies in breast cancer screening -- Digital breast tomosynthesis -- Automated whole-breast ultrasound -- Contrast-enhanced digital mammography -- MRI -- Breath testing -- Conclusion -- References -- Chapter 12 Prostate cancer prevention -- Rationale for prostate cancer prevention -- Risk factors -- Chronic inflammation of the prostate -- Smoking -- Obesity -- Chemoprevention -- 5-Alpha-Reductase Inhibitors (5-ARIs) -- Metformin -- Statins -- Dietary supplements -- Selenium and vitamin E -- Prostate cancer prevention clinical trials -- Trial end-points -- Study design -- Study cohorts -- Chemoprevention clinical trial programme -- Conclusion -- References -- Chapter 13 Population screening for prostate cancer -- Screening -- The malignancy should be an important health problem -- The natural history of PCa needs to be well understood -- Effective treatments for PCa should be available -- The screening test should be acceptable. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Adequate facilities should be available to deal with any abnormalities detected -- The benefits of screening should exceed the harms -- Future developments -- Conclusion -- References -- Chapter 14 Colon cancer prevention -- Genetic architecture of colorectal cancer -- Mutations and genetic variants -- Consensus molecular subtype classification -- Prevention strategies for colorectal cancer -- Lifestyle modifications and aspirin use -- Personalized chemoprevention with aspirin -- Biological mechanism of aspirin -- Germline variants -- Somatic mutations and gene expression -- Prescribing aspirin to the general and high‐risk populations -- Dose and duration -- Recommendations and considerations -- Future work and novel therapies -- Conclusion -- References -- Chapter 15 Colon cancer screening -- Rationale for CRC screening -- Overview of evidence -- Targets of screening -- Role of endoscopy versus indirect tests -- Stool blood testing -- Guaiac-based FOBT: RCT evidence of efficacy -- Faecal immunochemical testing: An improved stool test -- FIT and guidelines -- Challenges for the future -- FIT sensitivity in a programme of testing repeatedly over time -- Sigmoidoscopy -- Evidence of efficacy from RCTs -- International variability in the practice of sigmoidoscopy -- Sigmoidoscopy and guidelines -- Challenges for the future: Tailoring screening to risk -- Colonoscopy -- How effective could colonoscopy be in assuring low future CRC risk? -- Can the magnitude of colonoscopy protection be inferred from data from sigmoidoscopy RCTs? -- Can the magnitude of colonoscopy protection be inferred from non‐RCT studies? -- Colonoscopy quality: Very variable and very significant -- Challenges for the future -- Post-polypectomy surveillance -- Surveillance guidelines have varied over time and have at times been overaggressive -- Challenges for the future. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Screening guidelines -- Different recommendations -- Different processes -- Challenges for the future -- References -- Chapter 16 Lung cancer prevention -- The occurrence of lung cancer -- The causes of lung cancer and opportunities for prevention -- Tobacco smoking -- Air pollution -- Ionizing radiation -- Occupational factors -- Chemoprevention of lung cancer -- The burden of avoidable lung cancer -- Conclusion -- References -- Chapter 17 Lung cancer screening -- Screening for lung cancer: Early approaches -- Randomized controlled trials -- National Lung Screening Trial -- Subset analyses within the NLST -- The European Randomized Controlled Trials (RCT) -- False-positive examinations: A serious challenge -- Nodule measurement, definition of positive scan, and nodule management -- Radiation risk -- Recommendations for screening -- Risk-based models to better select screening populations -- Selection of high-risk individuals may reduce false-positive rate -- Screening in never smokers -- Cost-effectiveness -- Critical interface with smoking cessation programmes -- Implementation of screening programmes -- Conclusion -- References -- Chapter 18 Mesothelioma: Screening in the modern age -- Role of screening -- Identifying the at-risk population -- Screening methodologies -- The role of chest X-ray -- The role of computed tomography -- The role of circulating biomarkers -- Circulating biomarker studies for distinguishing MPM from controls -- Conclusion -- References -- Chapter 19 Skin cancer prevention and screening -- Causes of skin cancer -- Incidence -- Changes in incidence trends internationally: Are prevention efforts working? -- Cost of skin cancer -- Controversies in prevention -- Does sunscreen make things better or worse? -- Banning solariums and sunbeds -- Vitamin D -- Conclusions on prevention -- Population screening for melanoma. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | The absence of randomized trials. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Berg, Christine D. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Tobias, Jeffrey S. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Eeles, Rosalind A. |
| Title | Cancer Prevention and Screening |
| Place, publisher, and date of publication | Newark : John Wiley & Sons, Incorporated,c2018 |
| International Standard Book Number | 9781118990872 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5494679">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5494679</a> |
| Public note | Click to View |
No items available.